Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | GUSB | P08236 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10195447 | 0.90 | LMNA (0.45) | PLA2G10LMNAL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL10195444 | 0.86 | KDM4E (0.33) | LMNAKDM4EALDH1A1GUSBADAM17 | |
| SCHEMBL10195372 | 0.85 | PTGS1 (0.37) | LMNAKDM4EALDH1A1HPGDPDE4B | |
| SCHEMBL10195281 | 0.84 | HTT (0.41) | LMNAL3MBTL1KDM4EALDH1A1HPGD | |
| SCHEMBL10195244 | 0.82 | — | — | |
| SCHEMBL10195264 | 0.82 | SMN1; SMN2 (0.35) | ALDH1A1 | |
| SCHEMBL10195245 | 0.82 | SMN1; SMN2 (0.35) | ALDH1A1 | |
| SCHEMBL10195206 | 0.81 | PPARG (0.35) | — | |
| SCHEMBL10195278 | 0.81 | PDE4B (0.32) | PDE4B | |
| SCHEMBL10195072 | 0.81 | CAMK2A (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387569-B1 | HERBCIDES | SYNGENTA LTD (GB) | 2016-06-15 | — | — | EP | disclosed |
| US-20140378305-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2014-12-25 | — | — | US | disclosed |
| US-20140378305-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2014-12-25 | — | — | US | disclosed |
| US-8865623-B2 | Herbicidally active cyclic diones and derivatives thereof, processes for their preparation, compositions, and method of controlling weeds | SYNGENTA LIMITED (GB) | 2014-10-21 | — | — | US | disclosed |
| US-8865623-B2 | Herbicidally active cyclic diones and derivatives thereof, processes for their preparation, compositions, and method of controlling weeds | SYNGENTA LIMITED (GB) | 2014-10-21 | — | — | US | disclosed |
| US-20120021907-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120021907-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2010081755-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378305-A1 | NOVEL HERBICIDES | DDT, CYP4X1, CYP1B1 | PLA2G10 4084/4885LMNA 4151/4885L3MBTL1 3154/4885 |
| US-20120021907-A1 | NOVEL HERBICIDES | DDT, CYP4X1, CYP1B1 | PLA2G10 3867/4885LMNA 4657/4885L3MBTL1 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.